HROHep03 Cells
CAD$1,104.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | HROHep03 is a human hepatocellular adenocarcinoma cell line established from the primary liver tumor of a 71-year-old Caucasian female patient within the HRO biobank series of patient-derived tumor cell lines developed by PD Dr. Michael Linnebacher since 2006. The tumor was classified as a primary adenocarcinoma at TNM stage T0NxMx, grade 3, reflecting a high-grade hepatic adenocarcinoma without confirmed distant metastasis at the time of tissue harvest. HROHep03 grows as an adherent monolayer with fibroblast-like morphology and was confirmed free of human pathogenic viruses HBV, HCV, and HIV, consistent with the stringent quality control standards of the Linnebacher biobank series. The Cellosaurus accession is CVCL_2U72. HROHep03 is applicable in hepatocellular adenocarcinoma research, studies of high-grade liver tumor cell biology, drug sensitivity and resistance testing (sorafenib, cisplatin, 5-FU), liver tumor invasion and migration assays, and molecular pathway analysis. As part of the HRO biobank, this line provides a patient-specific biological resource that can be paired with matched immunological material from the same patient for personalized oncology research. Its fibroblast-like morphology distinguishes it phenotypically from the more common hepatocyte-like HCC lines and may reflect epithelial-to-mesenchymal features acquired during tumor progression or in vitro adaptation. HROHep03 is maintained as an adherent culture in DMEM:Ham’s F12 (1:1) supplemented with 10% FBS at 37°C in a humidified 5% CO₂ atmosphere. Cells are subcultured with Accutase when approximately 80–90% confluent. Medium is renewed every 3–5 days; after thawing, allow at least 2 days for recovery before the first medium change. |
|---|---|
| Organism | Human |
| Tissue | Liver |
| Disease | Primary adenocarcinoma, T0NxMx stage, grade 3 |
| Metastatic site | Not applicable (TNM stage T0NxMx; no confirmed distant metastasis at time of sample collection) |
| Applications | Hepatocellular adenocarcinoma research; high-grade HCC modeling; drug sensitivity testing (sorafenib, cisplatin, 5-FU); liver tumor invasion and migration; patient-matched HRO biobank studies |
Characteristics
| Age | 71 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Fibroblast-like |
| Cell type | Fibroblast-like (hepatocellular carcinoma) |
| Growth properties | Adherent |
Regulatory Data
| Citation | HROHep03 (Cytion catalog number 300197) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_2U72 |
| GMO Status | No genetic modification; wildtype patient-derived hepatic adenocarcinoma cell line established by PD Dr. Linnebacher. Confirmed free of HBV, HCV, HIV. |
Biomolecular Data
| Viruses | Free of human pathogenic viruses HBV, HCV, HIV. |
|---|
Handling
| Culture Medium | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | approx. 48 to 72 hours |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Split ratio | 1 to 3 |
| Seeding density | 2 x 104 cells/cm2 |
| Fluid renewal | Every 3 to 5 days |
| Post-Thaw Recovery | 2 days |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300197-117 | Certificate of Analysis | 23. May. 2025 | 300197 |
| 300197-219 | Certificate of Analysis | 23. May. 2025 | 300197 |